ChemBridge Corporation and ChemBridge Research Laboratories, Inc. (CRL) have entered into a multi-year collaboration in discovery chemistry with AstraZeneca (LON:AZN).
The terms of agreement included that ChemBridge and CRL scientists at Moscow and San Diego research sites will work closely with AstraZeneca scientists to develop highly advanced exclusive small molecule libraries enhancing AstraZeneca's global drug discovery effort.
According to Eugene Vaisberg, Chairman and CEO of ChemBridge Corporation and CRL:
"We are very pleased that after worldwide evaluation and due diligence AstraZeneca has selected ChemBridge and CRL as one of their chemistry partners.
This new agreement serves as yet another confirmation of the excellent capabilities of CRL and ChemBridge in the expertise-driven area of small molecule research.
We look forward to contributing our proven chemistry expertise to AstraZeneca's global drug discovery program."
Financial details of the said agreement were not disclosed further.
Find more details from the press release.
Comment Preview